1.38 Lartruvo, New Directions for Cancer Trials, Gene Expression Profiling, & Dr. Miriam Knoll
Jan 26, 2019•1 hr 38 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode we tackle Eli Lilly's drug Lartruvo (olaratumab) and the under-powered phase II trial that led to its FDA accelerated approval; a viewpoint in JAMA on new directions for cancer trials; and gene expression profiling for carcinoma of unknown primary. We end with an interview with Dr. Miriam Knoll of Hackensack Meridian Health on employment after residency or fellowship, residency training, and the medical specialty pipeline.
Back us on Patreon! www.patreon.com/plenarysession
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast